Atara Biotherapeutics Inc (ATRA) Shares Sold by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. lessened its holdings in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 6.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 86,617 shares of the biotechnology company’s stock after selling 6,357 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Atara Biotherapeutics were worth $1,434,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Artal Group S.A. raised its stake in Atara Biotherapeutics by 20.0% in the 3rd quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock valued at $9,930,000 after acquiring an additional 100,000 shares during the period. SG Americas Securities LLC bought a new stake in Atara Biotherapeutics in the 3rd quarter valued at $142,000. Russell Investments Group Ltd. bought a new stake in Atara Biotherapeutics in the 3rd quarter valued at $170,000. Alps Advisors Inc. raised its stake in Atara Biotherapeutics by 14.5% in the 3rd quarter. Alps Advisors Inc. now owns 30,095 shares of the biotechnology company’s stock valued at $498,000 after acquiring an additional 3,821 shares during the period. Finally, IndexIQ Advisors LLC raised its stake in Atara Biotherapeutics by 83.1% in the 3rd quarter. IndexIQ Advisors LLC now owns 42,177 shares of the biotechnology company’s stock valued at $698,000 after acquiring an additional 19,136 shares during the period. Institutional investors and hedge funds own 69.67% of the company’s stock.

A number of equities research analysts recently weighed in on ATRA shares. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. Jefferies Group restated a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, October 5th. ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. BidaskClub upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Finally, Goldman Sachs Group reiterated a “neutral” rating and set a $20.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $30.60.

In other news, EVP Gad Soffer sold 7,000 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $15.00, for a total transaction of $105,000.00. Following the sale, the executive vice president now directly owns 166,342 shares of the company’s stock, valued at approximately $2,495,130. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $13.47, for a total value of $59,268.00. Following the sale, the chief executive officer now directly owns 737,767 shares in the company, valued at $9,937,721.49. The disclosure for this sale can be found here. Insiders have sold a total of 190,688 shares of company stock worth $3,813,819 in the last quarter. Company insiders own 16.20% of the company’s stock.

Atara Biotherapeutics Inc (ATRA) opened at $29.50 on Monday. The firm has a market capitalization of $902.58, a price-to-earnings ratio of -8.50 and a beta of 1.27. Atara Biotherapeutics Inc has a 12-month low of $11.80 and a 12-month high of $30.90.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.05). equities analysts expect that Atara Biotherapeutics Inc will post -4 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Atara Biotherapeutics Inc (ATRA) Shares Sold by Schwab Charles Investment Management Inc.” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.thestockobserver.com/2018/01/22/atara-biotherapeutics-inc-atra-shares-sold-by-schwab-charles-investment-management-inc.html.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply